CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-01 | Frankenfield Christopher James Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −19,375 | 58,125 | ||
| 2025-01-01 | Frankenfield Christopher James Chief Financial Officer | Grant or award · Stock Option (right to buy) 10b5-1 | +251,000 | 251,000 | ||
| 2025-01-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Option exercise | +16,625 | 16,625 | ||
| 2025-01-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Option exercise · Restricted Stock Units | −16,625 | 49,875 | ||
| 2025-01-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2025-01-01 | Russo Rene PRESIDENT AND CEO | Option exercise | +44,250 | 244,883 | ||
| 2025-01-01 | Russo Rene PRESIDENT AND CEO | Option exercise · Restricted Stock Units | −44,250 | 132,750 | ||
| 2025-01-01 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +638,000 | 638,000 | ||
| 2025-01-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Option exercise 10b5-1 | +5,000 | 5,000 | ||
| 2025-01-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Option exercise · Restricted Stock Units 10b5-1 | −5,000 | 15,000 | ||
| 2025-01-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) 10b5-1 | +60,000 | 60,000 | ||
| 2024-12-18 | GILEAD SCIENCES, INC. 10% owner | Purchase | +1,759,978 | $1.04 | $1.8M | 9,105,451 |
| 2024-12-18 | GILEAD SCIENCES, INC. 10% owner | Purchase · Prefunded Warrants (right to buy) | +6,092,816 | $1.04 | $6.3M | 9,975,266 |
| 2024-10-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +26,000 | 26,000 | ||
| 2024-08-03 | Frankenfield Christopher James Chief Operating Officer | Grant or award · Stock Option (right to buy) | +52,000 | 52,000 | ||
| 2024-06-14 | Xu Yuan Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-14 | Bonstein Sara Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-14 | ROSS ROBERT W. Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-14 | Rossi Christina Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-14 | Clancy Paul J Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 |
Page 6 of 12 · 224 trades